A Phase 3 interventional study of GSK3511294 (Depemokimab) in Asthma, sponsored by GlaxoSmithKline. Completed at 137 sites in 14 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-01-15.
Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing depemokimab in Asthma — 3 open to participants now, 3 under way, 3 of them phase 3. depemokimab · Asthma.
Among the 10 studies testing depemokimab in Asthma, this one is the 2nd largest by enrollment, is one of 2 that started in 2022, is one of 7 in phase 3, and was the 6th registered.
4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.
Browse Asthma studies →3 of the 10 studies testing depemokimab in Asthma are open now, in 12 countries. Recruiting first, the newest first:
GlaxoSmithKline · Sites in United States
Ages 6–11
GlaxoSmithKline · Sites in United States, United Kingdom
Ages 12+
GlaxoSmithKline · Sites in United States, Belgium, Canada and 9 more countries
Ages 18+
By country, each count listing its studies:
depemokimab: first FDA approval 2025 (EXDENSUR), first EMA approval 2026. What it is approved for, and how studies give it, is on its page →
Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.
This study: 12 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2017; this study’s year is marked. 2 started in 2022.
This study's enrollment of 641 is above the median of 79 across 3,344 interventional studies indexed under Asthma.
Median enrollment 273 across the 10 interventional studies. Of the 7 that completed or were terminated, 7 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 10 have an industry lead sponsor. The 1 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
262 studies in Asthma by GlaxoSmithKline: 7 open now, 12 under way, 7 of them phase 3. Of 240 finished, 132 (55%) have results posted.
Among the 262 studies in Asthma by GlaxoSmithKline, this one is the 23rd largest by enrollment of the 238 interventional ones that give a count, is one of 2 that started in 2022, is one of 61 in phase 3, and was the 242nd registered.
GlaxoSmithKline’s Asthma studies by the year they started, since 1999.
1 of the studies testing depemokimab in Asthma that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07671001Phase 3GlaxoSmithKlineA Study of Depemokimab in Participants of 6 to 11 Years of Age | 2027-03-01 |
Add it to your calendar (.ics) → With an account.
Among the 10 studies testing depemokimab in Asthma, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among GlaxoSmithKline’s 262 in Asthma:
This tab as a report to print or save as PDF → With an account.
The purpose of this open-label 12-month extension study is to continue to characterize the long-term safety, efficacy and immunogenic profile of GSK3511294 (Depemokimab) in participants with severe asthma with an eosinophilic phenotype following completion of clinical studies 206713 or 213744.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Participants who meet the following based on results of Week 48 assessment from Study 206713 or Study 213744 or from a later result:
Other product/clinical study:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biological: GSK3511294 (Depemokimab)
GSK3511294 (Depemokimab) will be administered using a pre-filled safety syringe.
Number of Participants With Any Adverse Events (AEs) and Serious AEs (SAEs)
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. An SAE is any untoward medical occurrence that, at any dose: results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or any other situation according to medical or scientific judgment.
Time frame: Up to Week 56
Number of Participants With Worst Case Post-Baseline Positive Anti-GSK3511294 Antibodies (ADA)
Serum samples were collected for the determination of anti-GSK3511294 antibodies (ADA) using a validated electro-chemiluminescent immunoassay. The assay involved screening, confirmation and titration assays. If serum samples tested positive in the screening assay, they were considered 'potentially positive' and were further analyzed for specificity using the confirmation assay. Samples that confirmed positive in the confirmation assay were reported as 'positive'. Confirmed positive ADA samples were further characterized in the titration assay to quasi-quantitate the amount of ADA in the sample and were also further characterized in the Neutralizing antibody (Nab) assay. A participant was considered positive ADA if they had at least one positive worst case post-Baseline ADA result. Number of participants with worst case post-Baseline positive anti-GSK3511294 antibodies are presented.
Time frame: Up to Week 52
Number of Participants With Worst Case Post-Baseline Positive Neutralizing Antibodies
Blood samples were collected for the determination of positive neutralizing antibodies. Neutralizing antibody (NAb) test was only carried out on samples that were positive in the confirmatory binding antibody assay. A participant was considered positive for NAb if they had at least one positive worst case post-Baseline neutralizing antibody result. Number of participants with worst case post-Baseline positive neutralizing antibodies are presented.
Time frame: Up to Week 52
Annualized Rate of Clinically Significant Exacerbations
Clinically significant exacerbations recorded were defined as worsening of asthma requiring the use of systemic corticosteroids (CS) (such as intramuscular \[IM\], intravenous \[IV\] or oral) and/or hospitalization and/or Emergency Department (ED) visit. For all participants, IV or oral steroids (e.g., prednisone) for at least 3 days or a single IM corticosteroid dose is required. For participants on maintenance systemic corticosteroids, at least double the existing maintenance dose for at least 3 days is required. Exacerbations recorded in the electronic case report form (eCRF) were considered as verified clinically significant exacerbations and included in the analysis. Exacerbations separated by less than 7 days was treated as a continuation of the same exacerbation.
Time frame: Up to Week 52
Change From Baseline in Asthma Control Questionnaire-5 (ACQ-5) Score
The ACQ-5 is a five-item questionnaire developed as a measure of participants asthma symptom control. The questions are designed to be self-completed by the participant. The 5 questions enquired to recall how their asthma had been during the previous week and to respond about the frequency and/or severity of symptoms (nocturnal awakening, waking in the morning, activity limitation, shortness of breath and wheezing). The overall ACQ-5 response option is the mean score of all 5 questions representing 0 with no impairment/limitation and 6 as total impairment/ limitation. Higher scores indicated more limitations and lower score with better asthma control. Baseline was the value at Day 1 of the study. Change from Baseline was defined as value at the indicated time point minus Baseline value. Number of participants with analyzable data for one or more timepoints.
Time frame: Baseline (Day 1), Weeks 4, 8, 12, 20, 26, 28, 32, 40 and 52
Change From Baseline in St. George's Respiratory Questionnaire (SGRQ) Total Score at Weeks 26 and 52
The SGRQ is a 50-item patient-reported outcome tool used to measure Quality of Life in participants with airway obstruction diseases. The questions are designed to be self-completed by the participant. The total score was calculated by the symptom score, activity and impact score; and summarizing the impact of the disease on overall health status on 0-100 rating scale. Scores are expressed as a percentage of overall impairment where 100 representing worst possible health status and 0 indicating best possible health status. Higher scores indicating greater impairment of quality of life. Baseline was the value at Day 1 of the study. Change from Baseline was defined as value at the indicated time point minus Baseline value. Number of participants with analyzable data for one or more timepoints.
Time frame: Baseline (Day 1), Weeks 26 and 52
Change From Baseline in Pre-Bronchodilator Forced Expiratory Volume in One Second (FEV1) at Weeks 26 and 52
Forced Expiratory Volume in One Second (FEV1) is a measure of lung function and defined as the volume of air that can be forced out in one second after taking a deep breath. FEV1 was measured electronically by spirometry. Baseline was the value at Day 1 of the study. Change from Baseline in pre-bronchodilator FEV1 was defined as value at the indicated time point minus Baseline value. Number of participants with analyzable data for one or more timepoints.
Time frame: Baseline (Day 1), Weeks 26 and 52
Participants who successfully completed treatment in studies 206713 (NCT04719832), and 213744 (NCT04718103) were eligible to continue their treatment in this open-label extension study 212895.
| Milestone | Placebo in Previous Studies/GSK3511294 100 mg SC in Extension Study | GSK3511294 in Previous Studies/GSK3511294 100 mg SC in Extension Study |
|---|---|---|
| Started | 214 | 427 |
| Safety analysis set | 210 | 419 |
| Completed | 199 | 403 |
| Not completed | 15 | 24 |
| Withdrew: Adverse event | 1 | 1 |
| Withdrew: Lack of efficacy | 1 | 1 |
| Withdrew: Lost to follow-up | 5 | 4 |
| Withdrew: Physician decision | 1 | 0 |
| Withdrew: Withdrawal by subject | 3 | 10 |
| Withdrew: Data integrity and gcp violations | 4 | 8 |
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. An SAE is any untoward medical occurrence that, at any dose: results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or any other situation according to medical or scientific judgment.
| Participants | Placebo in Previous Studies/GSK3511294 100 mg SC in Extension Study | GSK3511294 in Previous Studies/GSK3511294 100 mg SC in Extension Study |
|---|---|---|
| Any AEs | 147 | 301 |
| Any SAEs | 21 | 38 |
Serum samples were collected for the determination of anti-GSK3511294 antibodies (ADA) using a validated electro-chemiluminescent immunoassay. The assay involved screening, confirmation and titration assays. If serum samples tested positive in the screening assay, they were considered 'potentially positive' and were further analyzed for specificity using the confirmation assay. Samples that confirmed positive in the confirmation assay were reported as 'positive'. Confirmed positive ADA samples were further characterized in the titration assay to quasi-quantitate the amount of ADA in the sample and were also further characterized in the Neutralizing antibody (Nab) assay. A participant was considered positive ADA if they had at least one positive worst case post-Baseline ADA result. Number of participants with worst case post-Baseline positive anti-GSK3511294 antibodies are presented.
| Participants | Placebo in Previous Studies/GSK3511294 100 mg SC in Extension Study | GSK3511294 in Previous Studies/GSK3511294 100 mg SC in Extension Study |
|---|---|---|
| Number of Participants With Worst Case Post-Baseline Positive Anti-GSK3511294 Antibodies (ADA) | 15 | 40 |
Blood samples were collected for the determination of positive neutralizing antibodies. Neutralizing antibody (NAb) test was only carried out on samples that were positive in the confirmatory binding antibody assay. A participant was considered positive for NAb if they had at least one positive worst case post-Baseline neutralizing antibody result. Number of participants with worst case post-Baseline positive neutralizing antibodies are presented.
| Participants | Placebo in Previous Studies/GSK3511294 100 mg SC in Extension Study | GSK3511294 in Previous Studies/GSK3511294 100 mg SC in Extension Study |
|---|---|---|
| Number of Participants With Worst Case Post-Baseline Positive Neutralizing Antibodies | 0 | 5 |
Clinically significant exacerbations recorded were defined as worsening of asthma requiring the use of systemic corticosteroids (CS) (such as intramuscular \[IM\], intravenous \[IV\] or oral) and/or hospitalization and/or Emergency Department (ED) visit. For all participants, IV or oral steroids (e.g., prednisone) for at least 3 days or a single IM corticosteroid dose is required. For participants on maintenance systemic corticosteroids, at least double the existing maintenance dose for at least 3 days is required. Exacerbations recorded in the electronic case report form (eCRF) were considered as verified clinically significant exacerbations and included in the analysis. Exacerbations separated by less than 7 days was treated as a continuation of the same exacerbation.
| Exacerbation per participant per year | Placebo in Previous Studies/GSK3511294 100 mg SC in Extension Study | GSK3511294 in Previous Studies/GSK3511294 100 mg SC in Extension Study |
|---|---|---|
| Annualized Rate of Clinically Significant Exacerbations | 0.58 (0.45 to 0.73) | 0.55 (0.47 to 0.66) |
The ACQ-5 is a five-item questionnaire developed as a measure of participants asthma symptom control. The questions are designed to be self-completed by the participant. The 5 questions enquired to recall how their asthma had been during the previous week and to respond about the frequency and/or severity of symptoms (nocturnal awakening, waking in the morning, activity limitation, shortness of breath and wheezing). The overall ACQ-5 response option is the mean score of all 5 questions representing 0 with no impairment/limitation and 6 as total impairment/ limitation. Higher scores indicated more limitations and lower score with better asthma control. Baseline was the value at Day 1 of the study. Change from Baseline was defined as value at the indicated time point minus Baseline value. Number of participants with analyzable data for one or more timepoints.
| Scores on a Scale | Placebo in Previous Studies/GSK3511294 100 mg SC in Extension Study | GSK3511294 in Previous Studies/GSK3511294 100 mg SC in Extension Study |
|---|---|---|
| Week 4 | -0.28 ± 0.056 | -0.16 ± 0.039 |
| Week 8 | -0.22 ± 0.056 | -0.19 ± 0.039 |
| Week 12 | -0.28 ± 0.055 | -0.22 ± 0.038 |
| Week 20 | -0.16 ± 0.058 | -0.16 ± 0.040 |
| Week 26 | -0.14 ± 0.055 | -0.12 ± 0.038 |
| Week 28 | -0.23 ± 0.057 | -0.24 ± 0.039 |
| Week 32 | -0.35 ± 0.057 | -0.25 ± 0.040 |
| Week 40 | -0.24 ± 0.065 | -0.16 ± 0.045 |
| Week 52 | -0.15 ± 0.059 | -0.11 ± 0.041 |
The SGRQ is a 50-item patient-reported outcome tool used to measure Quality of Life in participants with airway obstruction diseases. The questions are designed to be self-completed by the participant. The total score was calculated by the symptom score, activity and impact score; and summarizing the impact of the disease on overall health status on 0-100 rating scale. Scores are expressed as a percentage of overall impairment where 100 representing worst possible health status and 0 indicating best possible health status. Higher scores indicating greater impairment of quality of life. Baseline was the value at Day 1 of the study. Change from Baseline was defined as value at the indicated time point minus Baseline value. Number of participants with analyzable data for one or more timepoints.
| Scores on a Scale | Placebo in Previous Studies/GSK3511294 100 mg SC in Extension Study | GSK3511294 in Previous Studies/GSK3511294 100 mg SC in Extension Study |
|---|---|---|
| Week 26 | -5.00 ± 0.939 | -2.62 ± 0.641 |
| Week 52 | -4.75 ± 1.043 | -2.33 ± 0.713 |
Forced Expiratory Volume in One Second (FEV1) is a measure of lung function and defined as the volume of air that can be forced out in one second after taking a deep breath. FEV1 was measured electronically by spirometry. Baseline was the value at Day 1 of the study. Change from Baseline in pre-bronchodilator FEV1 was defined as value at the indicated time point minus Baseline value. Number of participants with analyzable data for one or more timepoints.
| Liters (L) | Placebo in Previous Studies/GSK3511294 100 mg SC in Extension Study | GSK3511294 in Previous Studies/GSK3511294 100 mg SC in Extension Study |
|---|---|---|
| Week 26 | 0.059 ± 0.0207 | 0.013 ± 0.0144 |
| Week 52 | 0.036 ± 0.0217 | -0.004 ± 0.0152 |
Collected over Up to Week 56. Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo in Previous Studies/GSK3511294 100 mg SC in Extension Study | 0/210 (0%) | 21/210 (10%) | 82/210 (39%) |
| GSK3511294 in Previous Studies/GSK3511294 100 mg SC in Extension Study | 0/419 (0%) | 38/419 (9.1%) | 178/419 (42.5%) |
| Event | Placebo in Previous Studies/GSK3511294 100 mg SC in Extension Study | GSK3511294 in Previous Studies/GSK3511294 100 mg SC in Extension Study |
|---|---|---|
| AsthmaRespiratory, thoracic and mediastinal disorders | 3/210 | 5/419 |
| Atrial fibrillationCardiac disorders | 2/210 | 2/419 |
| COVID-19Infections and infestations | 2/210 | 0/419 |
| PneumoniaInfections and infestations | 2/210 | 3/419 |
| Intervertebral disc protrusionMusculoskeletal and connective tissue disorders | 2/210 | 1/419 |
| Lower respiratory tract infectionInfections and infestations | 0/210 | 2/419 |
| Adams-Stokes syndromeCardiac disorders | 1/210 | 0/419 |
| Adrenal massEndocrine disorders | 1/210 | 0/419 |
| Intestinal obstructionGastrointestinal disorders | 1/210 | 0/419 |
| Oesophageal obstructionGastrointestinal disorders | 1/210 | 0/419 |
| Event | Placebo in Previous Studies/GSK3511294 100 mg SC in Extension Study | GSK3511294 in Previous Studies/GSK3511294 100 mg SC in Extension Study |
|---|---|---|
| NasopharyngitisInfections and infestations | 21/210 | 58/419 |
| Upper respiratory tract infectionInfections and infestations | 25/210 | 45/419 |
| COVID-19Infections and infestations | 15/210 | 28/419 |
| BronchitisInfections and infestations | 7/210 | 22/419 |
| HeadacheNervous system disorders | 7/210 | 18/419 |
| Respiratory tract infectionInfections and infestations | 3/210 | 16/419 |
| PharyngitisInfections and infestations | 8/210 | 15/419 |
| RhinitisInfections and infestations | 8/210 | 13/419 |
| InfluenzaInfections and infestations | 7/210 | 9/419 |
| Lower respiratory tract infectionInfections and infestations | 6/210 | 13/419 |
Baseline characteristics were reported for the Safety Analysis Set which included all participants who received at least one dose of open-label GSK3511294 in this extension study, excluding the participants from the sites with data integrity and GCP violation issues.
| Age, Continuous(Years) | Placebo in Previous Studies/GSK3511294 100 mg SC in Extension Study | GSK3511294 in Previous Studies/GSK3511294 100 mg SC in Extension Study | Total |
|---|---|---|---|
| Mean | 53.6 ± 15.84 | 55.5 ± 14.84 | 54.8 ± 15.19 |
| Sex: Female, Male(Participants) | Placebo in Previous Studies/GSK3511294 100 mg SC in Extension Study | GSK3511294 in Previous Studies/GSK3511294 100 mg SC in Extension Study | Total |
|---|---|---|---|
| Female | 128 | 248 | 376 |
| Male | 82 | 171 | 253 |
| Race/Ethnicity, Customized(Participants) | Placebo in Previous Studies/GSK3511294 100 mg SC in Extension Study | GSK3511294 in Previous Studies/GSK3511294 100 mg SC in Extension Study | Total |
|---|---|---|---|
| WHITE | 169 | 321 | 490 |
| ASIAN | 35 | 81 | 116 |
| AMERICAN INDIAN OR ALASKA NATIVE | 1 | 2 | 3 |
| BLACK OR AFRICAN AMERICAN | 5 | 15 | 20 |
Showing the first 100 of 137 sites across 14 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — IPD for this study will be made available via the Clinical Study Data Request site.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.
Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.
Data sharing details ↗ · clinicalstudydatarequest.com
Ran from Mar 2022 to primary completion in May 2025, 38 months.
Results were first posted in Jan 2026, 7 months after primary completion.
Of 173 industry-sponsored phase 3 interventional studies under Asthma, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 41. This study's 38 months is above that.
Counting every sponsor, half of 205 studies reached it within 27 months; a quarter within 14 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Depemokimab